The AI industry's legal and commercial reckoning is arriving at speed. Week one of the Musk vs. Altman trial opened in Oakland with a stunning admission — Grok was trained on OpenAI's models. OpenAI, meanwhile, landed on Amazon Bedrock the moment Microsoft's exclusivity agreement expired. The enterprise workforce is shifting hard: Meta and Microsoft cut 20,000+ jobs citing AI automation, even as Copilot crossed 20 million paid enterprise seats. In Washington, Congress moved on two fronts — voluntary AI standards and criminal penalties for AI impersonation. ChatGPT quietly launched ads for free users as internal revenue targets went unmet. And in the most consequential story of the week, Isomorphic Labs put the first AI-designed drug compounds into human trials — four years after AlphaFold changed everything. The future arrived. It just came with a lawsuit attached.

Musk v. Altman trial — Grok trained on OpenAI models

Week one opened in Oakland with a significant admission — Musk's xAI trained Grok on OpenAI's models, a revelation that could reshape the trial's trajectory and AGI governance debate.

OpenAI launches on Amazon Bedrock

The moment Microsoft's exclusivity agreement expired, OpenAI models went live on AWS Bedrock — opening access to millions of enterprise developers and marking a major shift in AI distribution strategy.

Meta + Microsoft cut 20K+ jobs, blame AI automation

Both companies cited AI automation in their largest recent cuts. At the same time Microsoft's Copilot crossed 20 million paid enterprise seats — the automation dividend and the human cost arriving simultaneously.

Congress moves on AI — standards and criminal penalties

Bipartisan action on two fronts: the American Leadership in AI Act sets voluntary standards, while the AI Fraud Accountability Act introduces criminal penalties for AI-powered impersonation.

ChatGPT launches ads amid missed revenue targets

OpenAI rolled out ads for free and Go tier users as a WSJ report revealed the company has missed its internal revenue targets — raising questions about the sustainability of its current cost structure.

Isomorphic Labs' AI drugs enter human trials

Four years after AlphaFold changed protein science, Isomorphic Labs has put the first AI-designed drug compounds into human clinical trials — a milestone that marks the real-world arrival of AI-driven medicine.